BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
Citi maintains buy on Aurobindo Pharma
Aurobindo Pharma is the top mid-cap pharma pick. Expect strong earnings per share growth for FY14-17. Company has been improving its balance sheet to drive re-rating.